Delving into the Latest Updates on Cisen Pharmaceutical Ltd. with Synapse

Overview

Tags

Urogenital Diseases

Neoplasms

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	6
Neoplasms	3
Endocrinology and Metabolic Disease	3
Nervous System Diseases	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	14

Top 5 Target	Count

PI3Ks x mTOR	2
APE1(DNA-(apurinic or apyrimidinic site) lyase)	1
DPP-4(Dipeptidyl peptidase IV)	1
PARP1 x PARP2	1
ATP synthase	1

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study to evaluate the bioequivalence of the test product, Selexipag tablets (strength: 0.4 mg), and the reference product, Uptravi® (strength: 0.4 mg), in healthy adult participants in the fasting and fed states.

主要研究目的：研究空腹和餐后状态下单次口服受试制剂司来帕格片（规格：0.4 mg，辰欣药业股份有限公司生产）与参比制剂司来帕格片（Uptravi®，规格：0.4 mg，Janssen Pharmaceutica NV生产）在健康参与者体内的药代动力学，评价空腹和餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂司来帕格片（规格：0.4 mg）和参比制剂司来帕格片（Uptravi®，规格：0.4 mg）在健康参与者中的安全性。

[Translation]

Primary study objectives: To study the pharmacokinetics of a single oral dose of the test preparation Selexipag tablets (0.4 mg, manufactured by Chenxin Pharmaceutical Co., Ltd.) and the reference preparation Selexipag tablets (Uptravi®, 0.4 mg, manufactured by Janssen Pharmaceutica NV) in healthy participants in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary study objectives: To evaluate the safety of the test preparation Selexipag tablets (0.4 mg) and the reference preparation Selexipag tablets (Uptravi®, 0.4 mg) in healthy participants.

Start Date22 Jul 2025

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

NCT07065968

/ Not yet recruitingPhase 2IIT

Teriflunomide and High-dose Dexamethasone vs High-dose Dexamethasone Alone as First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial

A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

Start Date15 Jul 2025

Sponsor / Collaborator

Peking University People's Hospital

[+2]

CTR20252350

/ RecruitingNot Applicable

维生素K1注射液人体生物等效性研究（口服给药）

[Translation] Bioequivalence study of vitamin K1 injection in humans (oral administration)

研究目的：本试验旨在研究健康研究参与者单次空腹和餐后口服辰欣药业股份有限公司研制、生产的维生素K1注射液（1 ml:10 mg）的药代动力学特征；以CHEPLAPHARM Arzneimittel GmbH生产的维生素K1注射液（Konakion®MM 10mg，1 ml:10 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性，并观察两制剂在健康研究参与者中的安全性。

[Translation]

Purpose of the study: This study aims to study the pharmacokinetic characteristics of vitamin K1 injection (1 ml:10 mg) developed and produced by Chenxin Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration in healthy study participants; using vitamin K1 injection (Konakion®MM 10 mg, 1 ml:10 mg) produced by CHEPLAPHARM Arzneimittel GmbH as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, evaluate the human bioequivalence of the two preparations, and observe the safety of the two preparations in healthy study participants.

Start Date09 Jul 2025

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

100 Clinical Results associated with Cisen Pharmaceutical Ltd.

Login to view more data

0 Patents (Medical) associated with Cisen Pharmaceutical Ltd.

Login to view more data

1

Literatures (Medical) associated with Cisen Pharmaceutical Ltd.

Dangdai Huagong Yanjiiu

Analysis on Safety Characteristics and Fault Diagnosis Technology of Chemical Machinery and Equipment

Author: Li Ruoqing

Chem. machinery and equipment is the key to the development of chem. enterprises, and it affects the production value and efficiency of chem. enterprises.With the continuous innovation of technol., the safety of many chem. machinery and equipment has been significantly improved.Based on the safety characteristics and fault diagnosis anal. of Huangong machinery and equipment, this paper focuses on the influence of safety characteristics of chem. machinery and equipment, explores the principle of failure of chem. machinery and equipment and the diagnosis content of chem. equipment, and strives to optimize the management measures of chem. machinery and equipment and reduce the failure frequency of chem. machinery and equipment.

100 Deals associated with Cisen Pharmaceutical Ltd.

Login to view more data

100 Translational Medicine associated with Cisen Pharmaceutical Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1

Phase 2

6

2

Phase 3

Approved

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fesoterodine Fumarate ( mAChRs )	Pollakisuria More	Phase 3
Sudapyridine ( ATP synthase )	Pulmonary Tuberculosis More	Phase 3
WXSH0102	Candidiasis, Vulvovaginal More	Phase 2
WXSH0208 ( influenza virus polymerase )	Influenza B virus infection More	Phase 2
WXSH0176	Colitis, Ulcerative More	Phase 2